HopeStage
Back to all studies
CompletedNCT07018245

Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder

Medication studyAges 18–65ChinaDepression
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
HangzhouSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 9, 2025
Recruitment status
Completed
Enrollment listed in the registry
149
Sponsor
Hangzhou PhecdaMed Co., Ltd.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT07018245
Official title
Show the full official title

A Phase II, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-GroupClinical Trial to Evaluate the Safety and Efficacy of TJ0113 Capsules in Patients withDepressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Hangzhou

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Hangzhou PhecdaMed Co., Ltd.

Did this study involve medication?

Yes. The study involved medication, including TJ0113 and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies